Market Downturn: America's Car-Mart (NASDAQ: CRMT), Oculis Holding AG (NASDAQ: OCS), and Others Face Significant Stock Declines Today

Font: Financial Modeling Prep  • Jun 01, 2026

• Legal probes and claims of misleading information drove significant stock drops for some companies.
• Clinical trial failures led to sharp declines for biopharmaceutical companies.
• Leveraged ETFs magnified losses, while broader health news influenced diagnostics sector investor decisions.

Several America's Car-Mart, Inc. (NASDAQ: CRMT), Oculis Holding AG (NASDAQ: OCS), Daily Target 2X Long RKLB ETF (NYSEARCA: RKLX), Astrotech Corporation (NASDAQ: ASTC), and Co-Diagnostics, Inc. (NASDAQ: CODX) are facing significant stock price declines today. These market losers are experiencing drops tied to specific company news and broader market factors.

America's Car-Mart saw its stock fall by 44.18%, or $5.43, to close at $6.86. This sharp decline occurs as Rosen Law Firm continues its investigation into the automotive retailer. The probe centers on claims that the company may have given materially misleading business information to its investors.

Shares of Oculis Holding AG dropped 36.09%, or $8.20, to $14.51. The biopharmaceutical company announced its Phase 3 DIAMOND trials for its product OCS-01 did not meet the main goal for treating diabetic macular edema. As a result, Oculis Holding AG will not seek FDA approval for this use, and a law firm has started an investigation.

Daily Target 2X Long RKLB ETF, a leveraged exchange-traded fund (ETF), decreased by 29.44%, or $30.35, to $72.75. An ETF is a fund that trades on stock exchanges. A leveraged ETF uses financial tools to amplify the returns of an underlying asset. In this case, Daily Target 2X Long RKLB ETF's large drop is because it aims for two times the daily percentage change of Rocket Lab USA, Inc. (NASDAQ: RKLB), magnifying the underlying stock's losses.

Astrotech Corporation fell 28.92% to $35.40, while Co-Diagnostics, Inc. declined 27.32% to $6.20. The recent World Health Organization declaration regarding an Ebola outbreak may be influencing the biodefense sector. This could shift investor attention and capital away from companies like Co-Diagnostics, Inc. if they are not directly involved in addressing the new health concern.

In summary, the day's major stock declines are driven by specific events. These include legal investigations, disappointing clinical trial results, and the mechanics of leveraged financial products. Broader health news also appears to be influencing investor decisions in the diagnostics sector.